Biotech Values

[DewDiligence]

Another gene-therapy deal—Bayer inks collaboration with (private) Dimension Therapeutics for hemophilia-A:

http://finance.yahoo.com/news/bayer-healthcare-dimension-therapeutics-develop-101200762.html

…Dimension Therapeutics will receive an upfront payment of $20 million and will be eligible for potential development and commercialization milestone payments of up to $232 million. Dimension Therapeutics will be responsible for all pre-clinical development activities and the Phase I/IIa clinical trial, with funding from Bayer.

Depending on the results of the Phase I/IIa clinical trial, Bayer will conduct the confirmatory Phase III trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of hemophilia A. Dimension Therapeutics is eligible to receive tiered royalties based on product sales.